全球充血性心臟衰竭药物市场研究报告 - 2023 年至 2030 年行业分析、规模、份额、成长、趋势和预测

全球充血性心臟衰竭药物市场需求预计将从 2022 年的 72.9 亿美元达到 2030 年近 242.8 亿美元的市场规模，2023-2030 年研究期间CAGR为 16.23%。

充血性心臟衰竭(CHF) 药物，也称为心臟衰竭药物或心臟药物，是一类用于管理和治疗充血性心臟衰竭的药物。充血性心臟衰竭是一种慢性疾病，患者的心臟停止有效泵血以满足身体的需要。它可能由各种潜在原因引起，例如冠状动脉疾病、高血压、心臟瓣膜疾病或心肌病变。

市场动态：

心臟衰竭发生率的增加通常与老化和生活方式因素有关，这推动了对充血性心臟衰竭药物的需求。随着全球人口老化，心臟衰竭风险较高的老年人口数量增多，进一步推动了这项需求。药物治疗的进步，包括新药物和联合疗法的开发，正在加强心臟衰竭的治疗。医疗保健提供者和患者意识的提高以及监管支持促进了 CHF 药物的采用。植入式心臟设备和远距医疗等技术进步补充了药物治疗并改善了患者护理。个人化医疗根据个人情况定製药物治疗方案，优化治疗结果。研究、临床试验和合作继续推动慢性心臟衰竭药物开发的创新，重点是改善患者的治疗结果和生活品质。

研究报告涵盖波特五力模型、市场吸引力分析和价值链分析。这些工具有助于清晰地了解行业结构并评估全球范围内的竞争吸引力。此外，这些工具也对全球充血性心臟衰竭药物市场的各个细分市场进行了包容性评估。充血性心臟衰竭药物产业的成长和趋势为本研究提供了整体方法。

区域分析：

本节涵盖区域前景，重点介绍北美、欧洲、亚太地区、拉丁美洲以及中东和非洲充血性心臟衰竭药物市场当前和未来的需求。此外，该报告重点关注所有主要地区各个应用领域的需求、估计和预测。

该研究报告还涵盖了市场主要参与者的全面概况以及对全球竞争格局的深入了解。充血性心臟衰竭药物市场的主要参与者包括拜耳公司、诺华公司、默克公司、阿斯特捷利康公司、百时美施贵宝公司、安进公司、勃林格殷格翰国际有限公司、辉瑞公司、强生公司Services , Inc.、大冢製药有限公司、礼来公司、诺和诺德公司。本节包含竞争格局的整体视图，包括各种策略发展，例如关键併购、未来产能、合作伙伴关係、财务概况、合作、新产品开发、新产品发布和其他发展。

如果您有任何客製化要求，请写信给我们。我们的研究团队可以根据您的需求提供客製化报告。

目录

第一章：前言

• 报告说明
  • 客观的
  • 目标受众
  • 独特的销售主张 (USP) 和产品
• 研究范围
• 研究方法论
  • 市场研究过程
  • 市场研究方法论

第 2 章：执行摘要

• 市集亮点
• 全球市场概况

第 3 章：充血性心臟衰竭药物 - 产业分析

• 简介 - 市场动态
• 市场驱动因素
• 市场限制
• 机会
• 产业动态
• 波特五力分析
• 市场吸引力分析
  • 按药品类别分類的市场吸引力分析
  • 按配销通路分類的市场吸引力分析
  • 市场吸引力分析：按地区

第 4 章：价值链分析

• 价值链分析
• 原料分析
  • 原料清单
  • 原料厂商清单
  • 主要原物料价格走势
• 潜在买家名单
• 行销管道
  • 直效行销
  • 间接行销
  • 行销通路发展趋势

第 5 章：全球充血性心臟衰竭药物市场分析：依药物类别

• 按药物类别概述
• 历史和预测数据
• 按药物类别分析
• ACE抑制剂
• 血管张力素 2 受体阻断剂
• β受体阻断剂
• 利尿剂
• 醛固酮拮抗剂
• 正性肌力药
• 其他的

第 6 章：全球充血性心臟衰竭药物市场分析：按分销管道

• 按配销通路分類的概览
• 历史和预测数据
• 按配销通路分析
• 医院药房
• 零售药局
• 网路药局

第 7 章：全球充血性心臟衰竭药物市场分析：按地理位置

• 区域展望
• 介绍
• 北美销售分析
  • 概览、历史与预测资料销售分析
  • 北美按细分市场销售分析
  • 北美按国家销售分析
  • 美国销售分析
  • 加拿大销售分析
  • 墨西哥销售分析
• 欧洲销售分析
  • 概览、历史与预测资料销售分析
  • 欧洲按细分市场销售分析
  • 欧洲按国家销售分析
  • 英国销售分析
  • 法国销售分析
  • 德国销售分析
  • 义大利销售分析
  • 俄罗斯销售分析
  • 欧洲其他地区销售分析
• 亚太地区销售分析
  • 概览、历史与预测资料销售分析
  • 亚太地区按细分市场销售分析
  • 亚太地区国家/地区销售分析
  • 中国销售分析
  • 印度销售分析
  • 日本销售分析
  • 韩国销售分析
  • 澳洲销售分析
  • 东南亚销售分析
  • 亚太地区其他地区销售分析
• 拉丁美洲销售分析
  • 概览、历史与预测资料销售分析
  • 拉丁美洲按细分市场销售分析
  • 拉丁美洲按国家销售分析
  • 巴西销售分析
  • 阿根廷销售分析
  • 秘鲁销售分析
  • 智利销售分析
  • 拉丁美洲其他地区销售分析
• 中东和非洲销售分析
  • 概览、历史与预测资料销售分析
  • 中东和非洲按细分市场销售分析
  • 中东和非洲国家销售分析
  • 沙乌地阿拉伯销售分析
  • 阿联酋销售分析
  • 以色列销售分析
  • 南非销售分析
  • 中东其他地区和非洲销售分析

第 8 章：充血性心臟衰竭药品公司的竞争格局

• 充血性心臟衰竭药物市场竞争
• 伙伴关係/协作/协议
• 併购
• 新产品发布
• 其他发展

第 9 章：公司简介

• 顶级公司市占率分析
• 市场集中度
• Bayer AG
• 公司简介
• 公司收入
• 产品
• 最近的发展
• Novartis AG
• 公司简介
• 公司收入
• 产品
• 最近的发展
• Merck & Co. Inc.
• 公司简介
• 公司收入
• 产品
• 最近的发展
• AstraZeneca
• 公司简介
• 公司收入
• 产品
• 最近的发展
• Bristol-Myers Squibb Company
• 公司简介
• 公司收入
• 产品
• 最近的发展
• Amgen Inc.
• 公司简介
• 公司收入
• 产品
• 最近的发展
• Boehringer Ingelheim International GmbH
• 公司简介
• 公司收入
• 产品
• 最近的发展
• Pfizer Inc.
• 公司简介
• 公司收入
• 产品
• 最近的发展
• Johnson & Johnson Services Inc.
• 公司简介
• 公司收入
• 产品
• 最近的发展
• Otsuka Pharmaceutical Co. Ltd.
• 公司简介
• 公司收入
• 产品
• 最近的发展
• Eli Lilly and Company
• 公司简介
• 公司收入
• 产品
• 最近的发展
• Novo Nordisk A/S.
• 公司简介
• 公司收入
• 产品
• 最近的发展

注意 - 在公司概况中，财务详细资讯和近期发展视情况而定，或者如果是私人公司，则可能不包括在内

The global demand for Congestive Heart Failure Drugs Market is presumed to reach the market size of nearly USD 24.28 BN by 2030 from USD 7.29 BN in 2022 with a CAGR of 16.23% under the study period 2023 - 2030.

Congestive Heart Failure (CHF) drugs, also known as heart failure medications or cardiac medications, are a class of pharmaceuticals used to manage and treat congestive heart failure-a chronic medical condition in which the heart stops pumping blood effectively to meet the body's needs. It can result from various underlying causes, such as coronary artery disease, hypertension, heart valve disorders, or cardiomyopathy.

MARKET DYNAMICS:

The increasing incidence of heart failure, often associated with aging and lifestyle factors, is driving the demand for congestive heart failure medications. As the global population ages, a larger demographic of elderly individuals at higher risk of heart failure further contributes to this demand. Advancements in drug therapies, including the development of new medications and combination therapies, are enhancing the management of heart failure. Increased awareness among healthcare providers and patients, along with regulatory support, fosters the adoption of CHF drugs. Technological advancements, such as implantable cardiac devices and telemedicine, complement drug therapies and improve patient care. Personalized medicine tailors drug regimens to individual profiles, optimizing treatment outcomes. Research, clinical trials, and collaborations continue to drive innovation in CHF drug development, focusing on improving patient outcomes and quality of life.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of congestive heart failure drugs. The growth and trends of congestive heart failure drugs industry provide a holistic approach to this study.

MARKET SEGMENTATION:

This section of the congestive heart failure drugs market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Drug Class

• ACE Inhibitors
• Angiotensin 2 Receptor Blockers
• Beta Blockers
• Diuretics
• Aldosterone Antagonists
• Inotropes
• Others

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

REGIONAL ANALYSIS:

This section covers the regional outlook, which accentuates current and future demand for the Congestive Heart Failure Drugs market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Congestive Heart Failure Drugs market include Bayer AG, Novartis AG, Merck & Co., Inc., AstraZeneca, Bristol-Myers Squibb Company, Amgen Inc., Boehringer Ingelheim International GmbH, Pfizer, Inc., Johnson & Johnson Services, Inc., Otsuka Pharmaceutical Co., Ltd., Eli Lilly and Company, Novo Nordisk A/S. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

TABLE OF CONTENTS

1 . PREFACE

• 1.1. Report Description
  • 1.1.1. Objective
  • 1.1.2. Target Audience
  • 1.1.3. Unique Selling Proposition (USP) & offerings
• 1.2. Research Scope
• 1.3. Research Methodology
  • 1.3.1. Market Research Process
  • 1.3.2. Market Research Methodology

2 . EXECUTIVE SUMMARY

• 2.1. Highlights of Market
• 2.2. Global Market Snapshot

3 . CONGESTIVE HEART FAILURE DRUGS - INDUSTRY ANALYSIS

• 3.1. Introduction - Market Dynamics
• 3.2. Market Drivers
• 3.3. Market Restraints
• 3.4. Opportunities
• 3.5. Industry Trends
• 3.6. Porter's Five Force Analysis
• 3.7. Market Attractiveness Analysis
  • 3.7.1 Market Attractiveness Analysis By Drug Class
  • 3.7.2 Market Attractiveness Analysis By Distribution Channel
  • 3.7.3 Market Attractiveness Analysis By Region

4 . VALUE CHAIN ANALYSIS

• 4.1. Value Chain Analysis
• 4.2. Raw Material Analysis
  • 4.2.1. List of Raw Materials
  • 4.2.2. Raw Material Manufactures List
  • 4.2.3. Price Trend of Key Raw Materials
• 4.3. List of Potential Buyers
• 4.4. Marketing Channel
  • 4.4.1. Direct Marketing
  • 4.4.2. Indirect Marketing
  • 4.4.3. Marketing Channel Development Trend

5 . GLOBAL CONGESTIVE HEART FAILURE DRUGS MARKET ANALYSIS BY DRUG CLASS

• 5.1 Overview by Drug Class
• 5.2 Historical and Forecast Data
• 5.3 Analysis by Drug Class
• 5.4 ACE Inhibitors Historic and Forecast Sales by Regions
• 5.5 Angiotensin 2 Receptor Blockers Historic and Forecast Sales by Regions
• 5.6 Beta Blockers Historic and Forecast Sales by Regions
• 5.7 Diuretics Historic and Forecast Sales by Regions
• 5.8 Aldosterone Antagonists Historic and Forecast Sales by Regions
• 5.9 Inotropes Historic and Forecast Sales by Regions
• 5.10. Others Historic and Forecast Sales by Regions

6 . GLOBAL CONGESTIVE HEART FAILURE DRUGS MARKET ANALYSIS BY DISTRIBUTION CHANNEL

• 6.1 Overview by Distribution Channel
• 6.2 Historical and Forecast Data
• 6.3 Analysis by Distribution Channel
• 6.4 Hospital Pharmacies Historic and Forecast Sales by Regions
• 6.5 Retail Pharmacies Historic and Forecast Sales by Regions
• 6.6 Online Pharmacies Historic and Forecast Sales by Regions

7 . GLOBAL CONGESTIVE HEART FAILURE DRUGS MARKET ANALYSIS BY GEOGRAPHY

• 7.1. Regional Outlook
• 7.2. Introduction
• 7.3. North America Sales Analysis
  • 7.3.1. Overview, Historic and Forecast Data Sales Analysis
  • 7.3.2. North America By Segment Sales Analysis
  • 7.3.3. North America By Country Sales Analysis
  • 7.3.4. United State Sales Analysis
  • 7.3.5. Canada Sales Analysis
  • 7.3.6. Mexico Sales Analysis
• 7.4. Europe Sales Analysis
  • 7.4.1. Overview, Historic and Forecast Data Sales Analysis
  • 7.4.2. Europe by Segment Sales Analysis
  • 7.4.3. Europe by Country Sales Analysis
  • 7.4.4. United Kingdom Sales Analysis
  • 7.4.5. France Sales Analysis
  • 7.4.6. Germany Sales Analysis
  • 7.4.7. Italy Sales Analysis
  • 7.4.8. Russia Sales Analysis
  • 7.4.9. Rest Of Europe Sales Analysis
• 7.5. Asia Pacific Sales Analysis
  • 7.5.1. Overview, Historic and Forecast Data Sales Analysis
  • 7.5.2. Asia Pacific by Segment Sales Analysis
  • 7.5.3. Asia Pacific by Country Sales Analysis
  • 7.5.4. China Sales Analysis
  • 7.5.5. India Sales Analysis
  • 7.5.6. Japan Sales Analysis
  • 7.5.7. South Korea Sales Analysis
  • 7.5.8. Australia Sales Analysis
  • 7.5.9. South East Asia Sales Analysis
  • 7.5.10. Rest Of Asia Pacific Sales Analysis
• 7.6. Latin America Sales Analysis
  • 7.6.1. Overview, Historic and Forecast Data Sales Analysis
  • 7.6.2. Latin America by Segment Sales Analysis
  • 7.6.3. Latin America by Country Sales Analysis
  • 7.6.4. Brazil Sales Analysis
  • 7.6.5. Argentina Sales Analysis
  • 7.6.6. Peru Sales Analysis
  • 7.6.7. Chile Sales Analysis
  • 7.6.8. Rest of Latin America Sales Analysis
• 7.7. Middle East & Africa Sales Analysis
  • 7.7.1. Overview, Historic and Forecast Data Sales Analysis
  • 7.7.2. Middle East & Africa by Segment Sales Analysis
  • 7.7.3. Middle East & Africa by Country Sales Analysis
  • 7.7.4. Saudi Arabia Sales Analysis
  • 7.7.5. UAE Sales Analysis
  • 7.7.6. Israel Sales Analysis
  • 7.7.7. South Africa Sales Analysis
  • 7.7.8. Rest Of Middle East And Africa Sales Analysis

8 . COMPETITIVE LANDSCAPE OF THE CONGESTIVE HEART FAILURE DRUGS COMPANIES

• 8.1. Congestive Heart Failure Drugs Market Competition
• 8.2. Partnership/Collaboration/Agreement
• 8.3. Merger And Acquisitions
• 8.4. New Product Launch
• 8.5. Other Developments

9 . COMPANY PROFILES OF CONGESTIVE HEART FAILURE DRUGS INDUSTRY

• 9.1. Top Companies Market Share Analysis
• 9.2. Market Concentration Rate
• 9.3. Bayer AG
  • 9.3.1. Company Overview
  • 9.3.2. Company Revenue
  • 9.3.3. Products
  • 9.3.4. Recent Developments
• 9.4. Novartis AG
  • 9.4.1. Company Overview
  • 9.4.2. Company Revenue
  • 9.4.3. Products
  • 9.4.4. Recent Developments
• 9.5. Merck & Co. Inc.
  • 9.5.1. Company Overview
  • 9.5.2. Company Revenue
  • 9.5.3. Products
  • 9.5.4. Recent Developments
• 9.6. AstraZeneca
  • 9.6.1. Company Overview
  • 9.6.2. Company Revenue
  • 9.6.3. Products
  • 9.6.4. Recent Developments
• 9.7. Bristol-Myers Squibb Company
  • 9.7.1. Company Overview
  • 9.7.2. Company Revenue
  • 9.7.3. Products
  • 9.7.4. Recent Developments
• 9.8. Amgen Inc.
  • 9.8.1. Company Overview
  • 9.8.2. Company Revenue
  • 9.8.3. Products
  • 9.8.4. Recent Developments
• 9.9. Boehringer Ingelheim International GmbH
  • 9.9.1. Company Overview
  • 9.9.2. Company Revenue
  • 9.9.3. Products
  • 9.9.4. Recent Developments
• 9.10. Pfizer Inc.
  • 9.10.1. Company Overview
  • 9.10.2. Company Revenue
  • 9.10.3. Products
  • 9.10.4. Recent Developments
• 9.11. Johnson & Johnson Services Inc.
  • 9.11.1. Company Overview
  • 9.11.2. Company Revenue
  • 9.11.3. Products
  • 9.11.4. Recent Developments
• 9.12. Otsuka Pharmaceutical Co. Ltd.
  • 9.12.1. Company Overview
  • 9.12.2. Company Revenue
  • 9.12.3. Products
  • 9.12.4. Recent Developments
• 9.13. Eli Lilly and Company
  • 9.13.1. Company Overview
  • 9.13.2. Company Revenue
  • 9.13.3. Products
  • 9.13.4. Recent Developments
• 9.14. Novo Nordisk A/S.
  • 9.14.1. Company Overview
  • 9.14.2. Company Revenue
  • 9.14.3. Products
  • 9.14.4. Recent Developments

Note - in company profiling, financial details and recent development are subject to availability or might not be covered in case of private companies

LIST OF TABLES

• Market Snapshot
• Drivers : Impact Analysis
• Restraints : Impact Analysis
• List of Raw Material
• List of Raw Material Manufactures
• List of Potential Buyers
• Analysis by Drug Class (USD MN)
• ACE Inhibitors Market Sales by Geography (USD MN)
• Angiotensin 2 Receptor Blockers Market Sales by Geography (USD MN)
• Beta Blockers Market Sales by Geography (USD MN)
• Diuretics Market Sales by Geography (USD MN)
• Aldosterone Antagonists Market Sales by Geography (USD MN)
• Inotropes Market Sales by Geography (USD MN)
• Others Market Sales by Geography (USD MN)
• Analysis Market by Distribution Channel (USD MN)
• Hospital Pharmacies Market Sales by Geography (USD MN)
• Retail Pharmacies Market Sales by Geography (USD MN)
• Online Pharmacies Market Sales by Geography (USD MN)
• Global Congestive Heart Failure Drugs Market Sales by Geography (USD MN)
• North America Market Analysis (USD MN)
• United State Market Analysis (USD MN)
• Canada Market Analysis (USD MN)
• Mexico Market Analysis (USD MN)
• Europe Market Analysis (USD MN)
• Europe Market Estimate by Country (USD MN)
• United Kingdom Market Analysis (USD MN)
• France Market Analysis (USD MN)
• Germany Market Analysis (USD MN)
• Italy Market Analysis (USD MN)
• Russia Market Analysis (USD MN)
• Spain Market Analysis (USD MN)
• Rest of Europe Market Analysis (USD MN)
• Asia Pacific Market Analysis (USD MN)
• China Market Analysis (USD MN)
• Japan Market Analysis (USD MN)
• India Market Analysis (USD MN)
• South Korea Market Analysis (USD MN)
• Australia Market Analysis (USD MN)
• South East Asia Market Analysis (USD MN)
• Rest of Asia Pacific Market Analysis (USD MN)
• Latin America Market Analysis (USD MN)
• Brazil Market Analysis (USD MN)
• Argentina Market Analysis (USD MN)
• Peru Market Analysis (USD MN)
• Chile Market Analysis (USD MN)
• Rest of Latin America Market Analysis (USD MN)
• Middle East & Africa Market Analysis (USD MN)
• Saudi Arabia Market Analysis (USD MN)
• UAE Market Analysis (USD MN)
• Israel Market Analysis (USD MN)
• South Africa Market Analysis (USD MN)
• Rest of Middle East and Africa Market Analysis (USD MN)
• Partnership/Collaboration/Agreement
• Mergers And Acquisition

LIST OF FIGURES

• Research Scope of Congestive Heart Failure Drugs Report
• Market Research Process
• Market Research Methodology
• Global Congestive Heart Failure Drugs Market Size, by Region (USD MN)
• Porters Five Forces Analysis
• Market Attractiveness Analysis by Drug Class
• Market Attractiveness Analysis by Distribution Channel
• Market Attractiveness Analysis by Region
• Value Chain Analysis
• Global Market Analysis by Drug Class (USD MN)
• ACE Inhibitors Market Sales by Geography (USD MN)
• Angiotensin 2 Receptor Blockers Market Sales by Geography (USD MN)
• Beta Blockers Market Sales by Geography (USD MN)
• Diuretics Market Sales by Geography (USD MN)
• Aldosterone Antagonists Market Sales by Geography (USD MN)
• Inotropes Market Sales by Geography (USD MN)
• Others Market Sales by Geography (USD MN)
• Global Market Analysis by Distribution Channel (USD MN)
• Hospital Pharmacies Market Sales by Geography (USD MN)
• Retail Pharmacies Market Sales by Geography (USD MN)
• Online Pharmacies Market Sales by Geography (USD MN)
• Global Market Sales (USD MN)
• North America Market Sales (USD MN)
• Europe Market Sales (USD MN)
• Asia Pacific Market Sales (USD MN)
• Latin America Market Sales (USD MN)
• Middle East & Africa Market Sales (USD MN)
• Recent Development in Industry
• Top Companies Market Share Analysis

Kindly note that the above listed are the basic tables and figures of the report and are not limited to the TOC.